ALNY - Alnylam Pharmaceuticals, Inc.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 186.46 |
| Open | 186.36 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 183.88 - 190.45 |
| 52 Week Range | 120.43 - 242.97 |
| Volume | |
| Avg. Volume | 754,163 |
| Market Cap | 23.039B |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.61 |
| Earnings Date | Jul 26, 2023 - Jul 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 247.87 |
Fair Value
Related Research
Simply Wall St.Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Alnylam Pharmaceuticals, Inc.'s ( NASDAQ:ALNY ) price-to-sales (or "P/S") ratio of 20.1x might make it look like a...
ZacksAlnylam (ALNY) Reports Positive Results From APOLLO-B Study
Alnylam (ALNY) announces positive interim analysis results from the phase III APOLLO-B study of patisiran to treat transthyretin-mediated amyloidosis with cardiomyopathy at the end of 18 months.
Business WireAlnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., May 20, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The results were presented at the Annual Congress of the Heart Failure Association of th
Insider MonkeyAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2023 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2023 Earnings Call Transcript May 4, 2023 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.4, expectations were $-1.76. Operator: Thank you for standing by and welcome to the Alnylam Pharmaceuticals First Quarter 2023 Financial Results Conference Call. As a reminder today’s conference call is being recorded. I would […]
ZacksAlnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues
Alnylam Pharmaceuticals (ALNY) reports better-than-expected first-quarter 2023 results. Givlaari, Oxlumo and the newly approved Amvuttra drive revenues for the company.
- Simply Wall St.
Alnylam Pharmaceuticals First Quarter 2023 Earnings: Beats Expectations
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) First Quarter 2023 Results Key Financial Results Revenue: US$319.3m (up 50...
ZacksAlnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of 28.93% and 3.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireAlnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
CAMBRIDGE, Mass., May 04, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.
Business WireAlnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
CAMBRIDGE, Mass., May 03, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 1:40 pm PT (4:40 pm ET) at the Encore Hotel in Las Vegas.
Business WireAlnylam Issues 2022 Corporate Responsibility Report
CAMBRIDGE, Mass., May 03, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report. This year’s edition reasserts our commitment to advancing pioneering RNAi science and supporting health equity. The company continues to take meaningful steps across each of our six corporate responsibility pillars to ensure everyone has access to essential health services and medicines. As the company further these efforts
BenzingaAlnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced preliminary data from their Phase I study of their experimental drug dubbed ALN-APP. ALN-APP is an investigational RNAi therapeutic targeting amyloid precursor protein (APP, a brain protein) in development for Alzheimer's disease and cerebral amyloid angiopathy (CAA). Patients treated with single-dose ALN-APP experienced dose-dependent, rapid and sustained reduction in cerebrospinal
ZacksMirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Mirum Pharmaceuticals, Inc. (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Reuters
UPDATE 1-Second judge says US not liable in Moderna COVID-19 vaccine patent case
Moderna Inc failed to persuade a Delaware federal judge on Wednesday to shift liability from the company to the U.S. government for alleged patent infringement by Moderna's COVID-19 vaccine. Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit.
ReutersSecond judge says US not liable in Moderna COVID-19 vaccine patent case
Moderna Inc failed to persuade a Delaware federal judge on Wednesday to shift liability from the company to the U.S. government for alleged patent infringement by Moderna's COVID-19 vaccine. Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit.
Business WireAlnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
CAMBRIDGE, Mass. & TARRYTOWN, N.Y., April 26, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).
GlobeNewswireRegeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
- Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date - - Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the Human Brain Using Alnylam's Proprietary C16 Platform - TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,
InvestorPlace3 Pharma Stocks That Could See a Surge in Demand in 2023
As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ:IBB) ticking upward, for the most part, this year, investors who dive into pharma stocks need to capitalize on the sector’s positive momentum. Many experts suggest that we are in the golden age of biotechnology, with scientific breakthroughs transforming how we treat and prevent diseases. Hence, pharma stocks to
- Zacks
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q1 Earnings? What You Should Know
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireAlnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
CAMBRIDGE, Mass., April 20, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May 4, 2023, before the U.S. financial markets open.
ZacksWhy Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
American City Business JournalsAlnylam CEO Yvonne Greenstreet sees growing the company as 'a wonderful challenge'
When Greenstreet joined the drugmaker as chief operating officer in 2016, it had yet to turn its RNA-silencing technology into commercial drugs. Now, it's a nine-figure company.
ZacksStrength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?
Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
InvestorPlace3 Growth Stocks That Could Disrupt the Healthcare Industry
Healthcare growth stocks are often sought out by investors looking for market disruptors. That’s because these stocks can potentially deliver high revenue growth, earnings, and stock price. As an evolving sector, the healthcare industry is seeing high demand for innovative solutions to high patient costs and technology-driven efficiency. Examples of healthcare growth stocks include pharmaceutical companies developing new drugs, medical device manufacturers creating innovative devices, and health
CNW GroupAlnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel.
Business WireAlnylam Announces Appointment of Peter Kellogg to Board of Directors
CAMBRIDGE, Mass., March 08, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience.